Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
Identifieur interne : 002A93 ( Main/Exploration ); précédent : 002A92; suivant : 002A94Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
Auteurs : R J Van Soest [Pays-Bas] ; A J Templeton [Suisse] ; F E Vera-Badillo [Canada] ; F. Mercier [France] ; G. Sonpavde [États-Unis] ; E. Amir [Canada] ; B. Tombal [Belgique] ; M. Rosenthal [Australie] ; M A Eisenberger [États-Unis] ; I F Tannock [Canada] ; R. De Wit [Pays-Bas]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (mortalité), Adénocarcinome (traitement médicamenteux), Agences internationales, Granulocytes neutrophiles (anatomopathologie), Humains, Invasion tumorale, Lymphocytes (anatomopathologie), Mâle, Prednisone (administration et posologie), Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Taux de survie, Taxoïdes (administration et posologie), Tumeurs osseuses (mortalité), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux), Tumeurs prostatiques résistantes à la castration (anatomopathologie), Tumeurs prostatiques résistantes à la castration (mortalité), Tumeurs prostatiques résistantes à la castration (traitement médicamenteux), Études de suivi.
- MESH :
- administration et posologie : Prednisone, Taxoïdes.
- anatomopathologie : Adénocarcinome, Granulocytes neutrophiles, Lymphocytes, Tumeurs prostatiques résistantes à la castration.
- mortalité : Adénocarcinome, Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Adénocarcinome, Tumeurs osseuses, Tumeurs prostatiques résistantes à la castration.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Agences internationales, Humains, Invasion tumorale, Mâle, Pronostic, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Taux de survie, Études de suivi.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (mortality), Adenocarcinoma (pathology), Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bone Neoplasms (drug therapy), Bone Neoplasms (mortality), Bone Neoplasms (secondary), Follow-Up Studies, Humans, International Agencies, Lymphocytes (pathology), Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Neutrophils (pathology), Prednisone (administration & dosage), Prognosis, Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (mortality), Prostatic Neoplasms, Castration-Resistant (pathology), Survival Rate, Taxoids (administration & dosage).
- MESH :
- chemical , administration & dosage : Prednisone, Taxoids.
- drug therapy : Adenocarcinoma, Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- mortality : Adenocarcinoma, Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- pathology : Adenocarcinoma, Lymphocytes, Neutrophils, Prostatic Neoplasms, Castration-Resistant.
- secondary : Bone Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Follow-Up Studies, Humans, International Agencies, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Survival Rate.
Abstract
The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and duration of initial androgen deprivation therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy.
DOI: 10.1093/annonc/mdu569
PubMed: 25515657
Affiliations:
- Australie, Belgique, Canada, France, Pays-Bas, Suisse, États-Unis
- Angleterre, Hollande-Méridionale, Maryland, Midlands de l'Ouest, Région de Bruxelles-Capitale, Victoria (État)
- Baltimore, Birmingham, Bruxelles, Melbourne, Rotterdam
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E97
- to stream PubMed, to step Curation: 002E19
- to stream PubMed, to step Checkpoint: 002E19
- to stream Ncbi, to step Merge: 002104
- to stream Ncbi, to step Curation: 002104
- to stream Ncbi, to step Checkpoint: 002104
- to stream Main, to step Merge: 002A93
- to stream Main, to step Curation: 002A93
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.</title><author><name sortKey="Van Soest, R J" sort="Van Soest, R J" uniqKey="Van Soest R" first="R J" last="Van Soest">R J Van Soest</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology r.vansoest@erasmusmc.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation></author><author><name sortKey="Templeton, A J" sort="Templeton, A J" uniqKey="Templeton A" first="A J" last="Templeton">A J Templeton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of Medical Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of Medical Oncology and Hematology, Kantonsspital St Gallen, St Gallen</wicri:regionArea><wicri:noRegion>St Gallen</wicri:noRegion></affiliation></author><author><name sortKey="Vera Badillo, F E" sort="Vera Badillo, F E" uniqKey="Vera Badillo F" first="F E" last="Vera-Badillo">F E Vera-Badillo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Mercier, F" sort="Mercier, F" uniqKey="Mercier F" first="F" last="Mercier">F. Mercier</name><affiliation wicri:level="1"><nlm:affiliation>Statprocess, Port-Mort, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Statprocess, Port-Mort</wicri:regionArea><wicri:noRegion>Port-Mort</wicri:noRegion><wicri:noRegion>Port-Mort</wicri:noRegion></affiliation></author><author><name sortKey="Sonpavde, G" sort="Sonpavde, G" uniqKey="Sonpavde G" first="G" last="Sonpavde">G. Sonpavde</name><affiliation wicri:level="3"><nlm:affiliation>UAB Comprehensive Cancer Center, University of Alabama, Birmingham, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UAB Comprehensive Cancer Center, University of Alabama, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Amir, E" sort="Amir, E" uniqKey="Amir E" first="E" last="Amir">E. Amir</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B" last="Tombal">B. Tombal</name><affiliation wicri:level="3"><nlm:affiliation>Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Urology, Cliniques Universitaires Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Rosenthal, M" sort="Rosenthal, M" uniqKey="Rosenthal M" first="M" last="Rosenthal">M. Rosenthal</name><affiliation wicri:level="3"><nlm:affiliation>Depertment of Oncology, Royal Melbourne Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Depertment of Oncology, Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M A" last="Eisenberger">M A Eisenberger</name><affiliation wicri:level="3"><nlm:affiliation>Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore</wicri:regionArea><placeName><settlement type="city">Baltimore</settlement><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tannock, I F" sort="Tannock, I F" uniqKey="Tannock I" first="I F" last="Tannock">I F Tannock</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Wit, R" sort="De Wit, R" uniqKey="De Wit R" first="R" last="De Wit">R. De Wit</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25515657</idno><idno type="pmid">25515657</idno><idno type="doi">10.1093/annonc/mdu569</idno><idno type="wicri:Area/PubMed/Corpus">002E97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E97</idno><idno type="wicri:Area/PubMed/Curation">002E19</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E19</idno><idno type="wicri:Area/PubMed/Checkpoint">002E19</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E19</idno><idno type="wicri:Area/Ncbi/Merge">002104</idno><idno type="wicri:Area/Ncbi/Curation">002104</idno><idno type="wicri:Area/Ncbi/Checkpoint">002104</idno><idno type="wicri:Area/Main/Merge">002A93</idno><idno type="wicri:Area/Main/Curation">002A93</idno><idno type="wicri:Area/Main/Exploration">002A93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.</title><author><name sortKey="Van Soest, R J" sort="Van Soest, R J" uniqKey="Van Soest R" first="R J" last="Van Soest">R J Van Soest</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology r.vansoest@erasmusmc.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation></author><author><name sortKey="Templeton, A J" sort="Templeton, A J" uniqKey="Templeton A" first="A J" last="Templeton">A J Templeton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of Medical Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada Department of Medical Oncology and Hematology, Kantonsspital St Gallen, St Gallen</wicri:regionArea><wicri:noRegion>St Gallen</wicri:noRegion></affiliation></author><author><name sortKey="Vera Badillo, F E" sort="Vera Badillo, F E" uniqKey="Vera Badillo F" first="F E" last="Vera-Badillo">F E Vera-Badillo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Mercier, F" sort="Mercier, F" uniqKey="Mercier F" first="F" last="Mercier">F. Mercier</name><affiliation wicri:level="1"><nlm:affiliation>Statprocess, Port-Mort, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Statprocess, Port-Mort</wicri:regionArea><wicri:noRegion>Port-Mort</wicri:noRegion><wicri:noRegion>Port-Mort</wicri:noRegion></affiliation></author><author><name sortKey="Sonpavde, G" sort="Sonpavde, G" uniqKey="Sonpavde G" first="G" last="Sonpavde">G. Sonpavde</name><affiliation wicri:level="3"><nlm:affiliation>UAB Comprehensive Cancer Center, University of Alabama, Birmingham, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UAB Comprehensive Cancer Center, University of Alabama, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Amir, E" sort="Amir, E" uniqKey="Amir E" first="E" last="Amir">E. Amir</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B" last="Tombal">B. Tombal</name><affiliation wicri:level="3"><nlm:affiliation>Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Urology, Cliniques Universitaires Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Rosenthal, M" sort="Rosenthal, M" uniqKey="Rosenthal M" first="M" last="Rosenthal">M. Rosenthal</name><affiliation wicri:level="3"><nlm:affiliation>Depertment of Oncology, Royal Melbourne Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Depertment of Oncology, Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M A" last="Eisenberger">M A Eisenberger</name><affiliation wicri:level="3"><nlm:affiliation>Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore</wicri:regionArea><placeName><settlement type="city">Baltimore</settlement><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Tannock, I F" sort="Tannock, I F" uniqKey="Tannock I" first="I F" last="Tannock">I F Tannock</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Wit, R" sort="De Wit, R" uniqKey="De Wit R" first="R" last="De Wit">R. De Wit</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (mortality)</term><term>Adenocarcinoma (pathology)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (mortality)</term><term>Bone Neoplasms (secondary)</term><term>Follow-Up Studies</term><term>Humans</term><term>International Agencies</term><term>Lymphocytes (pathology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Neutrophils (pathology)</term><term>Prednisone (administration & dosage)</term><term>Prognosis</term><term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (mortality)</term><term>Prostatic Neoplasms, Castration-Resistant (pathology)</term><term>Survival Rate</term><term>Taxoids (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (mortalité)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Agences internationales</term><term>Granulocytes neutrophiles (anatomopathologie)</term><term>Humains</term><term>Invasion tumorale</term><term>Lymphocytes (anatomopathologie)</term><term>Mâle</term><term>Prednisone (administration et posologie)</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taux de survie</term><term>Taxoïdes (administration et posologie)</term><term>Tumeurs osseuses (mortalité)</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (traitement médicamenteux)</term><term>Tumeurs prostatiques résistantes à la castration (anatomopathologie)</term><term>Tumeurs prostatiques résistantes à la castration (mortalité)</term><term>Tumeurs prostatiques résistantes à la castration (traitement médicamenteux)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Prednisone</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Prednisone</term><term>Taxoïdes</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Granulocytes neutrophiles</term><term>Lymphocytes</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma</term><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Lymphocytes</term><term>Neutrophils</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs osseuses</term><term>Tumeurs prostatiques résistantes à la castration</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Follow-Up Studies</term><term>Humans</term><term>International Agencies</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Invasiveness</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agences internationales</term><term>Humains</term><term>Invasion tumorale</term><term>Mâle</term><term>Pronostic</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taux de survie</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and duration of initial androgen deprivation therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>France</li><li>Pays-Bas</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Hollande-Méridionale</li><li>Maryland</li><li>Midlands de l'Ouest</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li></region><settlement><li>Baltimore</li><li>Birmingham</li><li>Bruxelles</li><li>Melbourne</li><li>Rotterdam</li></settlement></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Van Soest, R J" sort="Van Soest, R J" uniqKey="Van Soest R" first="R J" last="Van Soest">R J Van Soest</name></noRegion><name sortKey="De Wit, R" sort="De Wit, R" uniqKey="De Wit R" first="R" last="De Wit">R. De Wit</name></country><country name="Suisse"><noRegion><name sortKey="Templeton, A J" sort="Templeton, A J" uniqKey="Templeton A" first="A J" last="Templeton">A J Templeton</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Vera Badillo, F E" sort="Vera Badillo, F E" uniqKey="Vera Badillo F" first="F E" last="Vera-Badillo">F E Vera-Badillo</name></noRegion><name sortKey="Amir, E" sort="Amir, E" uniqKey="Amir E" first="E" last="Amir">E. Amir</name><name sortKey="Tannock, I F" sort="Tannock, I F" uniqKey="Tannock I" first="I F" last="Tannock">I F Tannock</name></country><country name="France"><noRegion><name sortKey="Mercier, F" sort="Mercier, F" uniqKey="Mercier F" first="F" last="Mercier">F. Mercier</name></noRegion></country><country name="États-Unis"><region name="Angleterre"><name sortKey="Sonpavde, G" sort="Sonpavde, G" uniqKey="Sonpavde G" first="G" last="Sonpavde">G. Sonpavde</name></region><name sortKey="Eisenberger, M A" sort="Eisenberger, M A" uniqKey="Eisenberger M" first="M A" last="Eisenberger">M A Eisenberger</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B" last="Tombal">B. Tombal</name></region></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Rosenthal, M" sort="Rosenthal, M" uniqKey="Rosenthal M" first="M" last="Rosenthal">M. Rosenthal</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25515657
|texte= Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25515657" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |